Dr. Vogelzang Discusses Cabozantinib's Dose Size

Nicholas J. Vogelzang, MD
Published: Wednesday, Jun 29, 2011

Nicholas J. Vogelzang, MD, head of the Genitourinary Cancer Section at the Comprehensive Cancer Centers of Nevada discusses the cabozantinib (XL184) dose size concerns, the drug accumulation effect that occurs, and alternative dosing strategies.
SELECTED
LANGUAGE
Nicholas J. Vogelzang, MD, head of the Genitourinary Cancer Section at the Comprehensive Cancer Centers of Nevada discusses the cabozantinib (XL184) dose size concerns, the drug accumulation effect that occurs, and alternative dosing strategies.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x